MPI - Cisplatin and APO010 abstracts selected by ESMO's Scientific Committee for poster presentation on its annual congress

2016-08-08

Hoersholm; August 8th, 2016 - Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ, USA) announces that 2 abstracts have been selected by the Scientific Committee for Poster Presentations at the Annual Congress of European Society of Medical Oncology - ESMO - held on October 7 - 11 2016 in Copenhagen, Denmark.
One presents Drug Response Prediction (DRP(TM)) data from Oncology Ventures immuno-oncology product APO010 for Multiple Myeloma and the other presents data from Drug Response Prediction on cisplatin for Lung Cancer (the same DRP is used for the liposomal formulation of cisplatin in Oncology Ventures LiPlaCis). ESMO is expected to be attended by around 20.000 professionals, scientists, doctors, patients, and students from all over the world.

ESMO is the leading European professional organisation for medical oncology. Comprising more than 13,000 oncology professionals from over 130 countries. ESMO is the society of reference for oncology education and information.

"Combining APO010 with DRP analysis will add a precision medicine element to immuno-oncology treatment of Multiple Myeloma. The DRP method will enable us to identify patients with high likelihood of response and thereby facilitate focused future trial design and patient recruitment to achieve clinical success. I look very much forward to the presentation of the prediction method at the largest oncology congress in Europe," Said Adjunct Professor Peter Buhl Jensen, M.D., CEO of Medical Prognosis Institute.
"Cisplatin is one of the most used chemotherapies in the world and there is a need for biomarkers to predict efficacy of the drug. A Proof of Concept clinical trial using the MPI DRP(TM) with LiPlaCis, a liposomal formulation of cisplatin in breast cancer, is currently recruiting patients prospectively and I expect the data to be presented for the DRP in lung cancer at this years' ESMO is supportive for the Breast Cancer study as well." Buhl Jensen further commented.

Further conference details will be announced once this has been communicated to MPI.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.
The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About APO010
APO010 is a multimeric form of FAS-ligand for immuno-cancer therapy with a unique mechanism of action. APO010 acts through the FAS-receptor leading to apoptosis of the malignant cells. APO010 is expected to act in synergy with other cancer immunology agents such as ipilimumab and PD-1/PD-L1 inhibitors. The drug candidate is complemented by a companion diagnostic technology (APO010 DRP(TM)) for enrichment of the patient population. APO010 was tested in 25 patients with solid tumors in a phase 1 study. The drug was well tolerated. Pre-clinical studies have revealed that APO010 is highly efficient in Multiple Myeloma. Therefore, a clinical proof of concept phase trial will be conducted in patients with Multiple Myeloma that have been pre-screened for sensitivity using the APO010 DRP(TM) technology.
There is a great need for effective treatment against Multiple Myeloma, and the market value was over 7 billion USD during 2014. Researchers estimate the value of the cancer immunotherapy market to 35 billion USD by 2023 (Citi GPS).

About Multiple Myeloma
Multiple Myeloma (bone marrow cancer) is a systemic malignancy in the blood, affecting plasma cells. The introduction of high-dose therapy with autologous stem cell support, and introduction of new therapies like the proteasome inhibitor bortezomib and IMIDs (thalidomide and lenalidomide) has improved the outcome. In spite of this, eventually all patients will experience progressive disease and continue into second and later lines of treatment. OV will approach this important clinical issue by introducing a novel systemic chemotherapeutic treatment together with a predictive biomarker test. Based on DRP(TM), APO010 will be developed for use in treatment of Multiple Myeloma.

About Cisplatin
Cisplatin is one of the most widely used drugs in the treatment of cancer due to its documented efficacy in a number of tumour types. Cisplatin is used in the treatment of large indications as lung cancer EU+US approximately 480,000 new cases annually), head and neck cancer (500,000 cases annually worldwide) bladder cancer (EU+US approximately 170,000 annually) and ovarian cancer (EU+US approximately 71,000 annually).
Oncology Venture - the drug development arm of MPI is developing a liposomal formulation of cisplatin, LiPlaCis. The lipid formulation in LiPlaCis is the answer to a well-established need for improving cisplatin therapy and improving the formulation of the drug, so that a more selective up-take of cisplatin administered takes place at the tumour sites. A mechanism called was incorporated into the liposomes designed to trigger the release of an encapsulated drug specifically in the tumour tissue. An enzyme especially present on tumors called secretory phospholipase A2 (sPLA2), is utilised to break down the LiPlaCis once it has accumulated in the cancer tissue. The lipid composition is tailored to be specifically sensitive to degradation by the sPLA2 enzyme and thereby for release of the encapsulated drug.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.                                                                Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                                                              E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                                                           Telephone +45 21 70 10 49

Certified Advisor: Ronny Farnebäck, Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden